Quantcast

Latest kidney cancer Stories

2009-03-09 08:00:00

More Than 75 Percent of Patients Diagnosed Have Small Renal Cell Tumors; Safe Interventional Radiology Treatment Shown Near 100 Percent Effective in Destroying Localized Tumors, Says Johns Hopkins Study SAN DIEGO, March 9 /PRNewswire-USNewswire/ -- Freezing kidney tumors -- using a safe minimally invasive interventional radiology treatment that kills the cancer 100 percent effectively without surgery -- should be the gold standard or first treatment option for all individuals with tumors...

bab2b4884c10f8a0c219c32d709d90811
2009-01-27 10:23:04

Large-scale data mining of gene networks in fruit flies has led researchers to a sensitive and specific diagnostic biomarker for human renal cell carcinoma, the most common type of kidney cancer. In the journal Science, published early online January 22, a team based at the University of Chicago shows that the biomarker known as SPOP is produced by 99 percent of clear cell renal cell carcinomas but not by normal kidney tissue. Physicians could use SPOP levels to confirm or rule out a...

2008-12-24 09:04:07

Kidney cancer is typically without symptoms until it has spread to other organs, when it is also the most difficult to treat. Newer chemotherapies show great promise for extending survival during later disease stages, but they can also be highly toxic.In one of the first discoveries of its kind, UC Davis Cancer Center researchers have identified ways to block a cancer gene's own repair mechanism and, in so doing, help make chemotherapy for kidney cancer more effective and better tolerated....

2008-11-05 09:00:34

Antigenics Inc. (NASDAQ: AGEN) reported results for the quarter ended September 30, 2008. The company incurred a net loss attributable to common stockholders of $11.1 million, or $0.17 per share, basic and diluted, for the third quarter of 2008, compared with a net loss attributable to common stockholders in the third quarter of 2007 of $11.0 million, or $0.24 per share, basic and diluted. For the nine months ended September 30, 2008, the company incurred a net loss attributable to common...

2008-11-04 00:00:05

U.S. researchers found aggressive, personalized treatment increases kidney cancer patient survival compared to the one-size-fits-all traditionally used. Researchers said the landmark University of California, Los Angeles, study of 1,500 patients will allow doctors to better predict which patients will do well and select those who may respond to targeted therapies. The one-size-fits-all approach traditionally used in kidney cancer treatment should be changed based on the results of the...

2008-10-23 12:00:26

Antigenics, a biotechnology company, has submitted a marketing authorization application to the European Medicines Agency requesting approval for Oncophage in earlier-stage, localized renal cell carcinoma under the conditional authorization provision. In advance of the marketing authorization application (MAA) submission, meetings with European Medicines Agency (EMEA) representatives, including the rapporteur countries, were convened to discuss the results from the international,...

2008-10-22 06:00:08

Antigenics Inc. (NASDAQ: AGEN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) requesting approval for Oncophage(R) in earlier-stage, localized renal cell carcinoma (kidney cancer) under the conditional authorization provision. Currently, there are no EMEA-approved drug therapies for this patient population. "The creation of the EMEA's conditional approval regulation provides an important mechanism for allowing patients...

2008-09-29 12:00:14

Antigenics Inc. (NASDAQ: AGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted the necessary permission to allow for the export of Oncophage (R) (vitespen) to Russia. The Russian Ministry of Public Health approved the therapeutic cancer vaccine in April 2008 for the adjuvant treatment of kidney cancer patients at intermediate risk for disease recurrence. The FDA export license clears the way to provide patients in Russia with Oncophage, which will continue to...

2008-09-10 18:00:08

By Martin Shipton A DAUGHTER whose father suffers from cancer has today appealed directly to Health Minister Edwina Hart for those in his position to be given the drugs that could prolong their lives. Anna Wolfenden's open letter to Ms Hart calls for a swift decision to be made about the availability of drugs such as Sunitinib that are widely available for patients with kidney cancer in the United States and other countries but have failed to secure the recommendation of NHS bodies in...

2008-09-05 06:00:23

Cancer drug developer Antisoma has started a Phase II study of AS1411 in metastatic renal cell carcinoma. The single-arm trial will enroll around 30 patients intolerant to, or having relapsed after, previous treatments including a tyrosine kinase inhibitor (sunitinib or sorafenib). It will evaluate the safety and efficacy of AS1411 monotherapy given at 40 mg/kg/day for four days every 28 days for up to two cycles. Efficacy measures in the trial include response rate, time to progression...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.